Professional
Added to YB: 2025-10-22
Pitch date: 2025-09-30
BEAM [neutral]
Beam Therapeutics Inc.
+14.53%
current return
Author Info
No bio for this author
Company Info
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
Market Cap
$3.2B
Pitch Price
$24.16
Price Target
N/A
Dividend
N/A
EV/EBITDA
-35.98
P/E
-50.32
EV/Sales
13.76
Sector
Biotechnology
Category
growth
Contrarius Global Equity Fund Portfolio Holding: Beam Therapeutics Inc.
BEAM (holding update): Base editing (CRISPR 2.0) swaps DNA bases without double-strand breaks, potentially safer than CRISPR-Cas9. Platform tech could work across diseases once proven. Phase 1/2 trials: GSD1a & AATD (100k US patients, no approved liver therapies). Partnerships w/ Pfizer/Apellis. Pipeline undervalued if platform succeeds.
Read full article (2 min)